Fatty Liver Disease clinical trials

Explore recruiting fatty liver disease clinical trials.

Recruiting fatty liver disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fatty Liver Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Spain, Poland, France, Italy, Bulgaria, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

17 β-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Nonalcoholic Steatohepatitis

Greece, Italy, Belgium, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of orlistat on LIVER fat content in obese subjects with NAFLD and High concEntrAtion of pLasma proneurotensin THrough inhibition of neurotensin secretion and action

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Control strategies and pharmacogenetic study for the personalized treatment of fatty liver associated with metabolic dysfunction in patients with prediabetes.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fatty Liver Disease trials by city

Fatty Liver Disease in Toronto Fatty Liver Disease in Vancouver Fatty Liver Disease in Montreal Fatty Liver Disease in Calgary Fatty Liver Disease in Edmonton Fatty Liver Disease in Ottawa Fatty Liver Disease in Winnipeg Fatty Liver Disease in Quebec City Fatty Liver Disease in Hamilton Fatty Liver Disease in Kitchener Fatty Liver Disease in London Fatty Liver Disease in Halifax Fatty Liver Disease in New York Fatty Liver Disease in Los Angeles Fatty Liver Disease in Chicago Fatty Liver Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease